These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 24423595)

  • 1. Parallelism: considerations for the development, validation and implementation of PK and biomarker ligand-binding assays.
    Stevenson LF; Purushothama S
    Bioanalysis; 2014 Jan; 6(2):185-98. PubMed ID: 24423595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What is going on with my samples? A general approach to parallelism assessment and data interpretation for biomarker ligand-binding assays.
    Ciotti S; Purushothama S; Ray S
    Bioanalysis; 2013 Aug; 5(16):1941-3. PubMed ID: 23937126
    [No Abstract]   [Full Text] [Related]  

  • 3. Validation of immunoassay for protein biomarkers: bioanalytical study plan implementation to support pre-clinical and clinical studies.
    Valentin MA; Ma S; Zhao A; Legay F; Avrameas A
    J Pharm Biomed Anal; 2011 Jul; 55(5):869-77. PubMed ID: 21530130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulatory considerations for development of bioanalytical assays for biotechnology products.
    Swann PG; Shapiro MA
    Bioanalysis; 2011 Mar; 3(6):597-603. PubMed ID: 21417729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Method validation and application of protein biomarkers: basic similarities and differences from biotherapeutics.
    Lee JW
    Bioanalysis; 2009 Nov; 1(8):1461-74. PubMed ID: 21083095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Method transfer for ligand-binding assays: recommendations for best practice.
    DeSimone D; Shih JY; Gunn HC; Patel V; Uy L; Thway TM
    Bioanalysis; 2011 Sep; 3(18):2143-52. PubMed ID: 21942524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tiered approach revisited: introducing stage-appropriate or assay-appropriate scientific validation.
    Timmerman P
    Bioanalysis; 2014 Mar; 6(5):599-604. PubMed ID: 24620801
    [No Abstract]   [Full Text] [Related]  

  • 8. Recommendations on biomarker bioanalytical method validation by GCC.
    Hougton R; Gouty D; Allinson J; Green R; Losauro M; Lowes S; LeLacheur R; Garofolo F; Couerbe P; Bronner S; Struwe P; Schiebl C; Sangster T; Pattison C; Islam R; Garofolo W; Pawula M; Buonarati M; Hayes R; Cameron M; Nicholson R; Harman J; Wieling J; De Boer T; Reuschel S; Cojocaru L; Harter T; Malone M; Nowatzke W
    Bioanalysis; 2012 Oct; 4(20):2439-46. PubMed ID: 23157353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery fit-for-purpose ligand-binding PK assays: what's really important?
    King LE; Leung S; Ray C
    Bioanalysis; 2013 Jun; 5(12):1463-6. PubMed ID: 23795921
    [No Abstract]   [Full Text] [Related]  

  • 10. Critical ligand binding reagent preparation/selection: when specificity depends on reagents.
    Rup B; O'Hara D
    AAPS J; 2007 May; 9(2):E148-55. PubMed ID: 17614357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and PK/PD evaluation in biotherapeutic drug development: scientific considerations for bioanalytical methods and data analysis.
    Wang YM; Jawa V; Ma M
    Bioanalysis; 2014 Jan; 6(1):79-87. PubMed ID: 24341496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: a conference report.
    Lee JW; Weiner RS; Sailstad JM; Bowsher RR; Knuth DW; O'Brien PJ; Fourcroy JL; Dixit R; Pandite L; Pietrusko RG; Soares HD; Quarmby V; Vesterqvist OL; Potter DM; Witliff JL; Fritche HA; O'Leary T; Perlee L; Kadam S; Wagner JA
    Pharm Res; 2005 Apr; 22(4):499-511. PubMed ID: 15846456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of commercial research-grade biomarker assays in drug development: is it time to create 'pharmaceutical-grade' kits?
    Bowsher RR; Nowatzke W; Sailstad JM; Khan MU
    Bioanalysis; 2012 Oct; 4(20):2427-30. PubMed ID: 23157350
    [No Abstract]   [Full Text] [Related]  

  • 14. Key elements of bioanalytical method validation for macromolecules.
    Kelley M; DeSilva B
    AAPS J; 2007 May; 9(2):E156-63. PubMed ID: 17614356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parallelism experiments in biomarker ligand-binding assays to assess immunological similarity.
    King LE
    Bioanalysis; 2016 Dec; 8(23):2387-2391. PubMed ID: 27855507
    [No Abstract]   [Full Text] [Related]  

  • 16. European Bioanalysis Forum recommendation: scientific validation of quantification by accelerator mass spectrometry.
    Higton D; Young G; Timmerman P; Abbott R; Knutsson M; Svensson LD
    Bioanalysis; 2012 Nov; 4(22):2669-79. PubMed ID: 23210650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules.
    DeSilva B; Smith W; Weiner R; Kelley M; Smolec J; Lee B; Khan M; Tacey R; Hill H; Celniker A
    Pharm Res; 2003 Nov; 20(11):1885-900. PubMed ID: 14661937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Applicability of bioanalysis of multiple analytes in drug discovery and development: review of select case studies including assay development considerations.
    Srinivas NR
    Biomed Chromatogr; 2006 May; 20(5):383-414. PubMed ID: 16307470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of immunoassays used to assess immunogenicity to therapeutic monoclonal antibodies.
    Geng D; Shankar G; Schantz A; Rajadhyaksha M; Davis H; Wagner C
    J Pharm Biomed Anal; 2005 Sep; 39(3-4):364-75. PubMed ID: 15963677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of analytical methods involved in dissolution assays: acceptance limits and decision methodologies.
    Rozet E; Ziemons E; Marini RD; Boulanger B; Hubert P
    Anal Chim Acta; 2012 Nov; 751():44-51. PubMed ID: 23084050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.